Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T93440
|
||||
Former ID |
TTDS00521
|
||||
Target Name |
Interleukin-6 receptor
|
||||
Synonyms |
CD126; IL-6R; IL6R; Membrane glycoprotein 80; gp80
|
||||
Target Type |
Successful
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Ankylosing spondylitis [ICD9: 720; ICD10: M08.1, M45] | |||||
Cutaneous lupus erythematosus [ICD9: 710; ICD10: M32] | |||||
Enthesopathy; Type 2 diabetes [ICD9:726, 250; ICD10: M76-M77.9, E11] | |||||
Juvenile idiopathic arthritis [ICD9: 714.3; ICD10: M08.0] | |||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Melanoma [ICD9: 172; ICD10: C43] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Severely active rheumatoid arthritis [ICD10: M05-M06] | |||||
Function |
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
|
||||
BioChemical Class |
Type I cytokine receptor
|
||||
Target Validation |
T93440
|
||||
UniProt ID | |||||
Drugs and Mode of Action | |||||
Drug(s) | Sarilumab | Drug Info | Approved | Severely active rheumatoid arthritis | [889446] |
Tocilizumab | Drug Info | Approved | Rheumatoid arthritis | [536711], [541938] | |
CHU | Drug Info | Registered | Enthesopathy; Type 2 diabetes | [548663] | |
CNTO-136 | Drug Info | Phase 3 | Cutaneous lupus erythematosus | [524294] | |
Fezakinumabx | Drug Info | Phase 3 | Rheumatoid arthritis | [525300] | |
SA-237 | Drug Info | Phase 3 | Rheumatoid arthritis | [524659] | |
SAR153191 | Drug Info | Phase 3 | Ankylosing spondylitis | [542912], [548704] | |
Tocilizumab | Drug Info | Phase 3 | Juvenile idiopathic arthritis | [536711], [541938] | |
ALX-0061 | Drug Info | Phase 2 | Autoimmune diabetes | [524991], [543089] | |
SBP-002 | Drug Info | Terminated | Melanoma | [548186] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
HIF-1 signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Reactome | MAPK3 (ERK1) activation | ||||
MAPK1 (ERK2) activation | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Senescence and Autophagy in Cancer | |||||
IL-6 signaling pathway | |||||
Differentiation Pathway | |||||
Interleukin-6 signaling | |||||
References | |||||
Ref 524294 | ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health. | ||||
Ref 524659 | ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health. | ||||
Ref 524991 | ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
Ref 525300 | ClinicalTrials.gov (NCT02531633) Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis. | ||||
Ref 536711 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | ||||
Ref 541938 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881). | ||||
Ref 542912 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7999). | ||||
Ref 543089 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363). | ||||
Ref 548186 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022850) | ||||
Ref 548663 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027532) | ||||
Ref 533248 | The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135. | ||||
Ref 543592 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.